Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 7/20 | 0.51 |
| ▸ | KLK5 | Q9Y337 | 6/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.46 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.46 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.44 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.44 |
| ▸ | STS | P08842 | 1/20 | 0.43 |
| ▸ | CETP | P11597 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.41 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19419776 | 1.00 | KLK7 (0.51) | KLK7KLK5PRSS1PRSS2PRSS3 | |
| SCHEMBL3728443 | 1.00 | KLK7 (0.51) | KLK7KLK5PRSS1PRSS2PRSS3 | |
| SCHEMBL598705 | 0.93 | KLK7 (0.45) | KLK7KLK5PRSS1PRSS2PRSS3 | |
| SCHEMBL598704 | 0.93 | KLK7 (0.45) | KLK7KLK5PRSS1PRSS2PRSS3 | |
| SCHEMBL6969013 | 0.91 | KLK7 (0.48) | KLK7KLK5PRSS1PRSS2PRSS3 | |
| SCHEMBL29997809 | 0.91 | KLK7 (0.48) | KLK7KLK5PRSS1PRSS2PRSS3 | |
| SCHEMBL12241769 | 0.89 | TP53 (0.45) | KLK7KLK5GPR119 | |
| SCHEMBL247530 | 0.88 | KLK7 (0.54) | KLK7KLK5PRSS1PRSS2PRSS3 | |
| SCHEMBL22154819 | 0.88 | KLK7 (0.39) | KLK7KLK5 | |
| SCHEMBL9929842 | 0.88 | FPR2 (0.39) | KLK7KLK5PRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096523-B2 | Process for preparing cyclic amine compounds | KANEKA CORPORATION (JP) | 2015-08-04 | — | — | US | disclosed |
| US-20130303771-A1 | PROCESS FOR PREPARING CYCLIC AMINE COMPOUNDS | KANEKA CORPORATION (JP) | 2013-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303771-A1 | PROCESS FOR PREPARING CYCLIC AMINE COMPOUNDS | SMS, SRM, PAM | KLK7 1811/4885KLK5 1886/4885PRSS1 2893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.